Marion Merrell Dow

WO 9 531 437 (Marion Merrell Dow appl. 28.4.1995 USA-prior. 11.4.1995,18.5.1994). improved bioavailability with high surface area particle form ... 

J. R. McCarthy, D. P. Matthews, and J. P. Paolini, Marion Merrell Dow Reseach Institute, 2110 E. Galbraith Road, Cincinnati, OH 45215... 

Marion Merrell Dow Research Institute, 2110 E. Galbraith Rd., Cincinnati, OH 45215. 

Gregory L. Kearns, PharmD, PhD Marion Merrell Dow/Missouri Chair in Medical Research, Professor of Pediatrics and Pharmacology, UMKC, Chair, Department of Medical Research, Associate Chairman, Department of Pediatrics, Chief, Division of Pediatric Pharmacology Medical Toxicology, Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA... 

Company Marion Merrell Dow Inc. Pratt Division / Pfizer Novartis... 

Affymax Marion Merrell Dow (5/91) Ciba-Geigy (7/91) American Home Products (2/94 3 CON targets 3 CON targets 11 CON targets... 

Hoechst, Roussel, Marion Merrel Dow, Rhone-Poulenc Sandoz, Ciba Geigy Squibb, Breistol-Myers... 

M A. see Mergers and acquisitions Management buyouts (MBO) 102 Managing Across Borders 122 Margin erosion 50, 81 Marion Merrell Dow 28, 34 Market... 

O 5. Triclofos ChloralOl Bonadorm Triclos Homer (Canada) Ferroson (Denmark) Marion Merrell Dow phenyl-3-pyrazolin-5-one compound with chloral hydrate 2,2,2-Trichloro ethanol, di-H- p.o. 500-1000... 

At the same time, Dow moved to bolster its position in pharmaceuticals by acquiring a leading mid-sized firm, Marion Laboratories. Dow consolidated its new property with Merrell-Dow Pharmaceutical and its Allied Laboratories to form Marion Merrell Dow, the ninth-largest pharmaceutical company in the United States. To finance this move, it took the company public while retaining 67 percent of its equity. ... 

In the mid-1990s Hoechst Celanese made two moves to support its new focus on pharmaceuticals. In 1995 it bought Marion Merrell Dow from Dow Chemical. At the end of the next year, Hoechst Celanese acquired the remaining interest in its French subsidiary Roussel Uclaf on the open market for 7.1 billion. It then combined these units into a new entity, Hoechst Marion Roussel (HMR). Then, in 1999, as further discussed in Chapter 9, HMR joined with Rhone-Poulenc Rorer in still another megamerger to produce Aventis. Following this deal, Aventis continued to spin off the chemical properties of its constituent companies, a story well beyond the scope of this book. 

In the words of a senior executive who advocated the purchase, Marion Laboratories had the premier sales organization in the United States. But, he added, It had no research worth the name, and fairly mediocre manufacturing facilities. Reality struck quickly. By 1993, earnings per share dropped sharply. Senior managers had become fully aware of the basic weaknesses due to the expiration of patents in its major businesses. Brandt, Growth Company, pp. 555-557, 560-564, provides an excellent review of the weaknesses of Marion Merrell Dow that led to its sale to Hoechst. See also Derdak, ed.. International Directory, vol. 9 (1994), pp. 32S-329 Hoover s Handbook (1996), p. 313. 

Marion Merrell Dow is counting on a late 1991 approval of Cardizem QD to give it time to convert patents from the immediate-release form of the diltiazem calcium channel blocker before the patent expires Nov. 5,1992, company management indicated at a Feb. 27 meeting with securities analysts in Kansas City, Missouri. 

Calling the approval of Cardizem QD Marion Merrell Dow s number one new product priority, MMD President Fred Lyons said I think it s possible that QD could be approved this year and introduced by the first of next year. ... 

To protect its 745 roil. Cardizem franchise, Marion Merrell Dow apparently intends to follow a strategy similar to the one Pfizer used to protect its nifedipine franchise from generics with sustained-release Procardia XL. Pfizer s strategy called for discounting the new generation product by 25 percent and promoting the price savings directly to consumers. Pfizer told analysts last fail that Procardia XL accounted for nearly two-thirds of all Procardia scripts one year after its launch in October 1989 ( The Pink Sheet nov. 5, p. 8). 

Marion Merrell Dow Prescription Products Division President David Roche outlined his company s strategy to convert patents from immediate-release Cardizem to the once-a-day formulation by pointing to his own experience in Canada as head of MMD s Nordic Labs subsidiary. Cardizem went off-patent in July 1988, the same time that Cardizem SR twice-a-day was approved. By discounting the sustained-release product by 5 percent and aggressively promoting it, Roche said, Nordic was able to maintain the total number of Cardizem prescriptions through 1990. 

Roche also said that like Pfizer, Marion Merrell Dow would seek to build patent brand loyalty to its Cardizem products. In addition, Roche said, Cardizem products will constitute SO percent plus of the... 

Levorin Candeptin Candimon. Candicidin antifungal. The major of four components of Candicin is Candicidin D ([1403-17-4]). White powder Xm = 403, 380 (E l Sm 1150), 360 nm insoluble in H2O, most organic solvents soluble in DMF, DMSO, AcOH LD50 (mus ip) = 14 mg/kg. Key Pham. Marion Merrell Dow Inc. 

---